Loading
Sentiment · FY2026 Q1
What companies say about each other on earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“But that comment on Centene was primarily around Medicaid experience which is kind of major medical coverage.”
Globe Life management distinguishes its Medicare Supplement business from Centene's recent negative headlines on medical cost trends, which were driven by Centene's Medicaid book rather than a market-wide issue.
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Andy Kligerman | TD Cowen | 13 (15%) |
| Jim Bhullar | JPMorgan | 13 (31%) |
| Jack Matten | BMO Capital Markets | 12 (17%) |
| Wilma Burdis | Raymond James | 11 (9%) |
| Wes Carmichael | Wells Fargo | 11 (18%) |
| Elyse Greenspan | Wells Fargo | 9 (0%) |
| John Barnidge | Piper Sandler | 9 (0%) |
| Suneet Kamath | Jefferies | 9 (11%) |
| Tom Gallagher | Evercore ISI | 8 (13%) |
| Ryan Krueger | KBW | 5 (20%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Wells Fargo | 2 | 20 (10%) |
| JPMorgan | 2 | 15 (27%) |
| TD Cowen | 1 | 13 (15%) |
| BMO Capital Markets | 1 |
| 12 (17%) |
| Raymond James | 1 | 11 (9%) |
| Jefferies | 1 | 9 (11%) |
| Piper Sandler | 1 | 9 (0%) |
| Evercore ISI | 1 | 8 (13%) |
Globe Life closed FY2025 with Q4 operating EPS of $3.39, up 8%, and full-year performance exceeding guidance. United American Medicare Supplement sales nearly doubled in 2025, and the Bermuda reinsurance entity was established with its first transaction executed. Management raised FY2026 guidance from $14.60-$15.30 to $14.95-$15.65, reflecting continued favorable mortality and health premium rate increases phasing in through 2027.
Demand | Margin | Capital Allocation | Innovation & R&D | Regulation Policy | Competitive Dynamics | Guidance Reliability | Pricing | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 5 | 4 | 8 | 1 | 3 | 1 | 1 | |
| 2025Q1 | 4 | 6 | 5 | 1 | 2 | 1 | 4 | |
| 2025Q2 | 12 | 6 | 9 | 4 | 2 | 3 | 3 | 1 |
| 2025Q3 | 9 | 6 | 5 | 2 | 2 | 3 | 5 | |
| 2025Q4 | 8 | 5 | 3 | 1 | 1 | 2 | 1 | 1 |
| 2026Q1 | 6 | 8 | 3 | 3 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 5 | 4 | 12 | 9 | 8 | 6 |
| Margin | 4 | 6 | 6 | 6 | 5 | 8 |
| Capital Allocation | 8 | 5 | 9 | 5 | 3 | 3 |
| Innovation & R&D | 1 | 1 | 4 | 2 | 1 | 3 |
| Regulation Policy | 3 | 2 | 2 | 2 | 1 | 1 |
| Competitive Dynamics | 1 | 3 | 3 | 2 | 1 | |
| Guidance Reliability | 1 | 3 | 5 | 1 | ||
| Pricing | 1 | 4 | 1 | 1 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
GL Globe Life | 8 | +5.3% | |
| AFL Aflac | 6 | +25.0% | |
| MET MetLife | 7 | +4.4% | |
| PRU Prudential Financial | 7 | +6.3% |